Announced
Financials
Tags
Private
Minority
Friendly
United States
Electronic Components and Equipment
Pending
culture technologies
Domestic
Single Bidder
Acquisition
Synopsis
Bio-Techne, a life sciences company, agreed to acquire a 20% stake in Wilson Wolf, a developer and manufacturer of cell culture technologies. Financial terms are not disclosed. "The explosive growth in cell and gene therapy is reminiscent of the monoclonal antibody field that Bio-Techne was founded on. CGT's lifesaving technology is now being touted as the 4th pillar of cancer treatment. The key to CGT lies in manufacturing simplicity, and we believe Wilson Wolf's G-Rex technology has the necessary attributes to bring CGT manufacturing to the simplest state while delivering the most robust cancer killing cells," Chuck Kummeth, Bio-Techne President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.